Oncology Corporate Profile
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company's first FDA-approved medication.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|mifepristone (+ eribulin)||progesterone receptor antagonist||Breast cancer||I|
|mifepristone||progesterone receptor antagonist||Breast cancer||I|
View additional information on product candidates here »